Press release
Investigation announced for NASDAQ:AVXL Investors over possible Wrongdoing at Anavex Life Sciences Corp.
An investigation on behalf of investors in Anavex Life Sciences Corp. (NASDAQ: AVXL) shares over potential wrongdoing.
Investors who purchased shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Anavex Life Sciences directors breached their fiduciary duties and caused damage to the company and its shareholders.
New York based Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Anavex Life Sciences Corp. reported that its Total Revenue rose from $30.93 million for the 12 months period that ended on September 30, 2020, to $41.94 million for the 12 months period that ended on September 30, 2021, and that its Net Loss over those time periods increased from $26.28 million to $37.9 million.
Before the market opened on February 1, 2022, Anavex Life Sciences Corp. announced that a phase 3 trial of ANAVEX2-73 (blarcamesine) for Rett syndrome met primary and secondary endpoints. Following the announcement, several people on social media indicated that the primary and secondary endpoints were recently changed. STAT's Adam Feuerstein tweeted, "Anavex changed the primary and secondary endpoints of this Rett study on Jan. 18, allowing it to claim success when the drug most likely failed."
Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) declined from $19.83 per share in December 2021 to as low as $9.93 per share on February 4, 2022.
Those who purchased shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for NASDAQ:AVXL Investors over possible Wrongdoing at Anavex Life Sciences Corp. here
News-ID: 2579452 • Views: …
More Releases from Shareholders Foundation
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, …
An investor, who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV), filed a lawsuit over alleged violations of Federal Securities Laws by DoubleVerify Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV) have certain options and for certain investors are short and strict deadlines running. Deadline: July 21, 2025. NYSE: DV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Investigation announced for Long-Term Investors in shares of Perpetua Resources …
An investigation was announced concerning possible breaches of fiduciary duties by certain directors and officers of Perpetua Resources Corp.
Investors who are current long term investors in Perpetua Resources Corp. (NASDAQ: PPTA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: PPTA stocks follows a lawsuit filed against Perpetua…
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Investor Alert: Deadline in Lawsuit …
A deadline is coming up on May 26, 2025 in the lawsuit filed for certain investors of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) over alleged securities laws violations by Actinium Pharmaceuticals, Inc.
Investors who purchased shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) have certain options and there are strict and short deadlines running. Deadline: May 26, 2025. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call…
Investigation announced for Long-Term Investors in shares of Rocket Lab USA, Inc …
An investigation was announced for long-term investors in shares of Rocket Lab USA, Inc. (NASDAQ: RKLB) concerning potential breaches of fiduciary duties by certain directors of Rocket Lab USA, Inc.
Investors who are current long term investors in Rocket Lab USA, Inc. (NASDAQ: RKLB) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long…
More Releases for Anavex
Investigation for Investors in NASDAW: AVXL shares over potential Securities Law …
An investigation on behalf of investors of Anavex Life Sciences Corp. (NASDAQ: AVXL) shares over potential securities laws violations by Anavex Life Sciences Corp. and certain of its directors and officers in connection with certain financial statements was announced.
Investors who purchased shares of Anavex Life Sciences Corp. (NASDAQ: AVXL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law…
Rett Syndrome Market Future Scope, Industry Growth, Demand, Region, Competitive …
LOS ANGELES, United States: The research study presented in this report offers a complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the global Rett Syndrome market. It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Rett Syndrome market. The authors of the report have segmented the global Rett Syndrome market as…
Progesterone Receptor Agonist Market 2020 Research and Clinical Analysis– Ther …
Progesterone Receptor Agonist -Pipeline Insight, 2020
The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Progesterone Receptor Agonist Market on the basis of stating current situation of the industry in 2020.
This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally.…
Rett Syndrome Treatment Market 2020 Size, Share, Trends Analysis 2027 Pointing t …
The Objective of Rett Syndrome Treatment Market Research Report is to provide a detailed analysis of industry and its impact based on applications and on different geographical regions, strategically analyses the growth trends, future prospects. Rett Syndrome Treatment Market Research Report is an in-depth evaluation of this industry, and a commendable brief of its segmentation. This report provides a basic overview of the market with respect to its current status…
Pain Drug Development Pipeline Review 2018 - Abide Therapeutics, Abiogen Pharma, …
Pain Drug Development Pipeline Review, 2018
Summary
This report provides an overview of the pipeline landscape for pain disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for post-operative pain, fibromyalgia, complex regional pain syndrome (CRPS) and visceral pain, and features dormant and discontinued products.
Pain is one of the main post-operative adverse outcomes causing distress to patients. Causes of post-operative pain include peripheral nerve…
Latest research on Muscarinic Acetylcholine Receptor M4 Market With top key play …
Up Market Research offers a latest published report on “Global Muscarinic Acetylcholine Receptor M4 Market Research Report 2019” delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 90 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.
Request Sample Copy Of this Report @ https://www.upmarketresearch.com/home/requested_sample/65022
Muscarinic Acetylcholine Receptor M4 Market research report…
